Prophylactic valaciclovir was effective and prevented herpes zoster in patients with systemic lupus erythematosus receiving anifrolumab, a treatment otherwise linked to an increased risk for herpes.
The use of valaciclovir as prophylaxis prevents herpes zoster in patients with systemic lupus erythematosus receiving anifrolumab treatment, with no cases of zoster reported during the follow-up period in patients receiving valaciclovir.Anifrolumab, a human monoclonal antibody binding to type I interferon receptor subunit 1, increases the risk for HZ in patients with SLE ; however, specific recommendations to prevent HZ are currently nonexistent for patients with SLE receiving anifrolumab.
Among these patients, 87 received either 500 mg/d valaciclovir or 1000 mg/d valaciclovir as prophylaxis, whereas 45 did not receive valaciclovir.
Systemic Lupus Erythaematosus SLE Systemic Lupus Erythematosus (SLE) Lupus Herpes Zoster Shingles France French Prophylaxis Artificial Intelligence Deep Learning AI NPL Machine Learning ML Natural Language Processing Artificial Neural Networks Grant Monoclonal Antibody Cetuximab Rituximab Neuralgia Receptors Biologic Therapy Biologics
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novel Digital Intervention Shows Promise for DepressionInterRhythmic care may help improve depressive and anxiety symptoms, interpersonal problems, and social function in patients with major depressive disorder.
Read more »
Active Surveillance Shows Promise as Alternative to Surgery for Low-Risk DCISA large trial, the COMET trial, found no clinically meaningful difference in the rates of ipsilateral invasive breast cancer between women who underwent active surveillance and those who had standard upfront surgery with or without radiation. The trial, which monitored lesions for changes indicating conversion to more advanced disease, aims to determine the safety and effectiveness of active surveillance as an alternative to immediate surgery for low-risk ductal carcinoma in situ (DCIS).
Read more »
New Drug Shows Promise for Newly Diagnosed Pediatric ITPA study found that children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy showed significantly improved platelet responses and other outcomes compared with the standard of care. This represents a potential breakthrough in treatment for this rare autoimmune blood disorder.
Read more »
DTI Shows Promise in Detecting Pancreatic Cancer LesionsA new study suggests that Diffusion Tensor Imaging (DTI) could be a valuable tool for detecting pancreatic cancer in its early stages.
Read more »
Teva, Sanofi Drug Shows Promise in Treating Crohn's, Ulcerative ColitisA study of a drug by Teva Pharmaceutical Industries and Sanofi showed promising results in treating Crohn's disease and ulcerative colitis, meeting key goals. The drug, duvakitug, demonstrated significant clinical remission rates in patients compared to a placebo.
Read more »
Neural Stem Cell Transplantation Shows Promise for Treating Chronic Spinal Cord InjuriesNew research on mice and rats suggests that transplanting neural stem cells combined with intensive physical therapy could lead to significant improvements in treating chronic spinal cord injuries.
Read more »